UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (1), p.30-39

2005

Volltextzugriff (PDF)

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

JNCI : Journal of the National Cancer Institute, 2003-12, Vol.95 (23), p.1758-1764

2003

Volltextzugriff (PDF)

Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays

The Journal of pharmacology and experimental therapeutics, 2001-12, Vol.299 (3), p.849

2001

Volltextzugriff (PDF)

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9312-9318

2005

Volltextzugriff (PDF)

Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3903-3911

2006

Volltextzugriff (PDF)

GREB1 is a critical regulator of hormone dependent breast cancer growth

Breast cancer research and treatment, 2005-07, Vol.92 (2), p.141-149

2005

Volltextzugriff (PDF)

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.277-287

2017

Volltextzugriff (PDF)

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

Breast cancer research and treatment, 2005-06, Vol.91 (3), p.249-258

2005

Volltextzugriff (PDF)

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

Breast cancer research and treatment, 2004-05, Vol.85 (2), p.151-159

2004

Volltextzugriff (PDF)

Abstract P6-12-05: Targeting estrogen receptor mutations for treatment of endocrine therapy resistance in breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-12-05

2017

Volltextzugriff (PDF)

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

Pharmacogenomics and personalized medicine, 2021-01, Vol.14, p.319-326

2021

Volltextzugriff (PDF)

Functional characterization of the G162R and D216H genetic variants of human CYP17A1

The Journal of steroid biochemistry and molecular biology, 2018-04, Vol.178, p.159-166

2018

Volltextzugriff (PDF)

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Molecular cancer therapeutics, 2005-02, Vol.4 (2), p.197-205

2005

Volltextzugriff (PDF)

Abstract P6-09-02: Analysis of the International tamoxifen pharmacogenomics consortium (ITPC) dataset shows that genotyping DNA derived from tumor does not introduce CYP2D6 genotyping error or mask an association with tamoxifen efficacy

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-09-02

2016

Volltextzugriff (PDF)

Abstract P6-13-05: Androgen receptor (AR): A novel target and mechanism for radiosensitization and treatment in triple-negative breast cancers (TNBC)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-13-05

2016

Volltextzugriff (PDF)

Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-09-11

2017

Volltextzugriff (PDF)

Abstract P3-07-36: Immune related gene expression signatures predict benefit of letrozole over tamoxifen in BIG 1-98

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-36

2016

Volltextzugriff (PDF)

Abstract S4-05: Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S4-S4-05

2016

Volltextzugriff (PDF)

Abstract P3-07-23: CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: An evaluation of the importance of loss-of-heterozygosity

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-23

2016

Volltextzugriff (PDF)

Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD7-07-PD7-07

2017

Volltextzugriff (PDF)

Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-02-19

2016

Volltextzugriff (PDF)

Abstract P3-07-64: Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-64

2016

Volltextzugriff (PDF)

Abstract P5-12-05: CYP3A422 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-12-05

2016

Volltextzugriff (PDF)

Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-05-01

2016

Volltextzugriff (PDF)

Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S3-S3-02

2016

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(185)

Publikationsform

Sprache

Englisch
(203)
Japanisch
(30)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(172)
Life Sciences & Biomedicine
(131)
Humans
(88)
Biological And Medical Sciences
(61)
Female
(47)
Male
(47)
Medical Sciences
(44)
Animals
(38)
Adult
(30)
Technology
(29)
Middle Aged
(26)
Physical Sciences
(26)
Pharmacology & Pharmacy
(20)
Aged
(19)
Fundamental And Applied Biological Sciences. Psychology
(19)
Oncology
(18)
Pharmacology. Drug Treatments
(17)
Physics
(17)
Neurosciences & Neurology
(15)
Rats
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors

GREB1 is a critical regulator of hormone dependent breast cancer growth

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

Abstract P6-12-05: Targeting estrogen receptor mutations for treatment of endocrine therapy resistance in breast cancer

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

Functional characterization of the G162R and D216H genetic variants of human CYP17A1

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Abstract P6-09-02: Analysis of the International tamoxifen pharmacogenomics consortium (ITPC) dataset shows that genotyping DNA derived from tumor does not introduce CYP2D6 genotyping error or mask an association with tamoxifen efficacy

Abstract P6-13-05: Androgen receptor (AR): A novel target and mechanism for radiosensitization and treatment in triple-negative breast cancers (TNBC)

Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

Abstract P3-07-36: Immune related gene expression signatures predict benefit of letrozole over tamoxifen in BIG 1-98

Abstract S4-05: Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance

Abstract P3-07-23: CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: An evaluation of the importance of loss-of-heterozygosity

Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients

Abstract P3-07-64: Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer

Abstract P5-12-05: CYP3A422 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC)

Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814

Suchergebnisse filtern